1. Immunotherapeutic targets in non‐small cell lung cancer.
- Author
-
Sadeghirad, Habib, Bahrami, Tayyeb, Layeghi, Sepideh M., Yousefi, Hassan, Rezaei, Meysam, Hosseini‐Fard, Seyed R., Radfar, Payar, Warkiani, Majid E., O'Byrne, Ken, and Kulasinghe, Arutha
- Subjects
NON-small-cell lung carcinoma ,TUMOR microenvironment ,THERAPEUTICS ,ENDOTHELIAL cells ,CELLULAR signal transduction - Abstract
Non‐small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5‐year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in‐depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF